newsfilter
← Latest News
Business Wire·

Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

Kite, a Gilead Company (NASDAQ:GILD), and Arcellx, Inc. (NASDAQ:ACLX), today announced the closing of the companies' previously announced global strategic collaboration to co-develop and co-commercialize Arcellx's lead